Absci (ABSI) Non-Current Deffered Revenue (2021 - 2026)
Absci's (ABSI) quarterly Non-Current Deffered Revenue came in at $641000.0 in Q1 2026, up 47.02% quarter-over-quarter from $436000.0 in Q4 2025.
Absci (ABSI) Non-Current Deffered Revenue (2021 - 2026) Analysis & Trends
Absci has disclosed Non-Current Deffered Revenue across 5 years of filings, most recently posting $641000.0 for Q1 2026.
- Non-Current Deffered Revenue for Q1 2026 came in at $641000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $641000.0 (changed N/A YoY), and the FY2025 annual result was $436000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue came in at $641000.0 for Q1 2026 at Absci, up from $436000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $966000.0 in Q4 2023 to a low of $180000.0 in Q1 2024.
- The 4-year median for Non-Current Deffered Revenue is $538500.0 (2025), against an average of $555750.0.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Absci | 1.13 Bn | 1.01 Bn | - | 641,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 641,000.00 |
| Dec 31, 2025 | 436,000.00 |
| Mar 31, 2024 | 180,000.00 |
| Dec 31, 2023 | 966,000.00 |
| Sep 30, 2021 | 122,000.00 |
| Jun 30, 2021 | 839,000.00 |